Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoldonrasib monotherapy in previously treated RAS G12D-mutant non-small cell lung cancer
NL-OMON58774Phase 2Active, not recruiting
- Sponsor
- Revolution Medicines
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zoldonrasib in non-small cell lung cancer (NSCLC), sponsored by Revolution Medicines. Primary endpoint: Confirmed objective response rate. Started Nov 2025; status: active, not recruiting.
02
Drugs
zoldonrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON58774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58774.